TransVIHMI, Université Montpellier, Inserm, IRD, Montpellier, France.
ARCAD Santé PLUS, Bamako, Mali.
Lancet HIV. 2021 Jul;8(7):e420-e428. doi: 10.1016/S2352-3018(21)00005-9. Epub 2021 May 25.
HIV pre-exposure prophylaxis (PrEP) data in men who have sex with men (MSM) in west Africa are essential to guide its large-scale implementation. We assessed the uptake of event-driven and daily PrEP, HIV incidence, and changes over time in sexual behaviours and prevalence of bacterial sexually transmitted infections (STIs) in MSM in Burkina Faso, Côte d'Ivoire, Mali, and Togo.
We did a prospective cohort study from Nov 20, 2017, to April 14, 2020, in four community-based clinics in Abidjan (Côte d'Ivoire), Bamako (Mali), Lomé (Togo), and Ouagadougou (Burkina Faso). Participants were MSM aged 18 years or older at substantial risk of HIV infection. Participants could choose between event-driven (2+1+1 dosing) and daily oral PrEP (tenofovir disoproxil fumarate 300 mg plus emtricitabine 200 mg), switch regimen, and discontinue or restart PrEP. We compared HIV incidence in this study with that of the same cohort before the availability of PrEP (CohMSM). Statistical analysis included the Kaplan-Meier method and mixed-effects regression models. This study is registered with ClinicalTrials.gov, NCT03459157.
We followed up 598 participants for a total of 743·6 person-years. At enrolment, 445 (74%) of 598 participants chose event-driven PrEP and 153 (26%) of 598 chose daily PrEP. 60 (13%) of 445 and 65 (42%) of 153 participants switched PrEP regimen at least once (p<0·0001). 159 participants (27%) were lost to follow-up. Overall HIV incidence was 2·3 per 100 person-years (95% CI 1·3-3·7; adjusted incidence rate ratio 0·21, 95% CI 0·12-0·36 compared with CohMSM). Adherence was optimal in 802 (41%) of 1946 measures with event-driven PrEP and in 394 (71%) of 554 measures with daily PrEP (p<0·0001). Coverage of sex acts with PrEP only and PrEP and condom decreased during follow-up (p=0·039 if PrEP only; p=0·0025 if PrEP and condom). The frequency of condomless anal sex remained stable (p=0·96). The number of male sexual partners (p<0·0001) and number of sex acts with casual male partners (p=0·0014 for 1-4 sex acts in previous 4 weeks; p=0·030 for ≥5 sex acts) decreased. The prevalence of gonorrhoea, chlamydia, and syphilis remained stable.
PrEP availability helped prevent HIV infection and did not lead to an increase in risky sexual behaviours or other STIs. PrEP should be urgently implemented in west Africa. Retention in care and PrEP adherence require special attention to ensure PrEP reaches its full prevention potential.
ANRS and Expertise France.
For the French translation of the abstract see Supplementary Materials section.
在西非,男男性行为者(MSM)的 HIV 暴露前预防(PrEP)数据对于指导其大规模实施至关重要。我们评估了布基纳法索、科特迪瓦、马里和多哥的 MSM 中事件驱动和每日 PrEP 的采用情况、HIV 发病率以及性行为和细菌性性传播感染(STI)流行率随时间的变化。
我们在 2017 年 11 月 20 日至 2020 年 4 月 14 日期间在科特迪瓦阿比让、马里巴马科、多哥洛美和布基纳法索瓦加杜古的四个社区诊所进行了一项前瞻性队列研究。参与者为有感染 HIV 风险的 18 岁或以上的 MSM。参与者可以选择事件驱动(2+1+1 剂量)和每日口服 PrEP(替诺福韦二吡呋酯 300mg 加恩曲他滨 200mg),也可以更换方案,还可以停止或重新开始 PrEP。我们将这项研究中的 HIV 发病率与 PrEP 可用之前(CohMSM)的同一队列进行了比较。统计分析包括 Kaplan-Meier 法和混合效应回归模型。本研究在 ClinicalTrials.gov 注册,编号为 NCT03459157。
我们对 598 名参与者进行了总计 743.6 人年的随访。入组时,445 名(74%)参与者选择了事件驱动 PrEP,153 名(26%)参与者选择了每日 PrEP。445 名参与者中有 60 名(13%)和 153 名参与者中有 65 名(42%)至少一次更换了 PrEP 方案(p<0·0001)。159 名参与者(27%)失访。总体 HIV 发病率为每 100 人年 2.3 例(95%CI 1.3-3.7;与 CohMSM 相比,调整后的发病率比为 0.21,95%CI 0.12-0.36)。在使用事件驱动 PrEP 的 1946 次措施中,有 802 次(41%)达到了最佳的依从性,在使用每日 PrEP 的 554 次措施中,有 394 次(71%)达到了最佳的依从性(p<0·0001)。在随访期间,仅使用 PrEP 和 PrEP 加避孕套进行性行为的比例下降(仅使用 PrEP 时 p=0·039;同时使用 PrEP 和避孕套时 p=0·0025)。无保护肛交的频率保持稳定(p=0·96)。性伴侣人数(p<0·0001)和与偶然的男性性伴侣发生性行为的次数(在过去 4 周内 1-4 次性行为时 p=0·0014;≥5 次性行为时 p=0·030)减少。淋病、衣原体和梅毒的患病率保持稳定。
PrEP 的可及性有助于预防 HIV 感染,且不会导致性行为风险增加或其他性传播感染。PrEP 应在西非紧急实施。为了确保 PrEP 发挥其全部预防潜力,需要特别关注患者的保留率和 PrEP 的依从性。
法国国家艾滋病研究署和 Expertise France。